Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Selinexor

    Client Email Product
    Renejix: CDMO with expertise in small molecule oral dosage, delivery tech, and multi-modality manufacturing.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Ribobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Selinexor

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Antengene To Commercialise XPOVIO In Thailand For Myeloma
    Antengene To Commercialise XPOVIO In Thailand For Myeloma

    23 Sep 2024

    // BIOSPECTRUM ASIA

    https://www.biospectrumasia.com/news/25/24928/antengene-receives-approval-to-commercialise-xpovio-in-thailand-for-multiple-myeloma-patients.html

    BIOSPECTRUM ASIA
    23 Sep 2024
    Share Share
    Karyopharm Reports Q2 2024 Results And Recent Progress
    Karyopharm Reports Q2 2024 Results And Recent Progress

    06 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/karyopharm-reports-second-quarter-2024-financial-results-and-highlights-recent-company-progress-302215439.html

    PR NEWSWIRE
    06 Aug 2024
    Share Share
    Antengene Announces XPOVIO® (Selinexor) Approved in Malaysia
    Antengene Announces XPOVIO® (Selinexor) Approved in Malaysia

    05 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/antengene-announces-xpovio-selinexor-approved-for-commercialization-in-malaysia-302214114.html

    PR NEWSWIRE
    05 Aug 2024
    Share Share
    XPOVIO (Selinexor) Approved For DLBCL In China, Offering New Treatment Option
    XPOVIO (Selinexor) Approved For DLBCL In China, Offering New Treatment Option

    05 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/xpovio-selinexor-approved-for-new-indication-in-dlbcl-in-china-bringing-a-new-treatment-option-to-patients-in-the-country-302190017.html

    PR NEWSWIRE
    05 Jul 2024
    Share Share
    Antengene's XPOVIO® Approved For Reimbursement In South Korea
    Antengene's XPOVIO® Approved For Reimbursement In South Korea

    26 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/antengene-announces-xpovio-selinexor-national-health-insurance-service-approval-for-reimbursement-in-south-korea-302182936.html

    PR NEWSWIRE
    26 Jun 2024
    Share Share
    Onco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO
    Onco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO

    13 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240313022739/en

    BUSINESSWIRE
    13 Mar 2024
    Share Share